What is Dimed Distribuidora de Medicamentos Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Dec. 2024, Dimed Distribuidora de Medicamentos has a Sloan Ratio of -1.87%, indicating the company is in the safe zone and there is no funny business with accruals.
Dimed Distribuidora de Medicamentos Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Dimed Distribuidora de Medicamentos Sloan Ratio % Chart
Competitive Comparison of Dimed Distribuidora de Medicamentos's Sloan Ratio %
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's Sloan Ratio % falls into.
Dimed Distribuidora de Medicamentos Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2024, Dimed Distribuidora de Medicamentos has a Sloan Ratio of -1.87%, indicating the company is in the safe zone and there is no funny business with accruals.
Dimed Distribuidora de Medicamentos Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Dimed Distribuidora de Medicamentos's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Dimed Distribuidora de Medicamentos Business Description
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. Its segments are divided into Retail, Wholesale and Corporate. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. The Wholesale segment is the distributor of drugs in Brazil. The Corporate segment includes Wholesale and Retail, as well as the subsidiary Lifar. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:PNVL3 has been successfully added to your 